peIF4E as an independent prognostic factor and a potential therapeutic target in diffuse infiltrating astrocytomas

Cancer Medicine

Volumn 5, Issue 9, 2016, Pages 2501-2512

  Martínez Sáez, Elena ^a,b   Peg, Vicente ^a,b   Ortega Aznar, Arantxa ^a   Martínez Ricarte, Francisco ^a   Camacho, Jessica ^a,b   Hernández Losa, Javier ^a   Ferreres Piñas, Joan Carles ^c   Ramón y Cajal, Santiago ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Hospital Universitari Parc Taulí   (Spain)

Author keywords

Astrocytomas; cell signaling; glioblastoma; peIF4E; prognosis

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; ISOCITRATE DEHYDROGENASE 1; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN S6;

ADULT; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER GROWTH; CANCER INFILTRATION; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DIFFUSE INFILTRATING ASTROCYTOMA; DRUG TARGETING; FEMALE; GENE MUTATION; GLIOBLASTOMA; GLIOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR BIOPSY;

EID: 84991096584     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.817     Document Type: Article

References (37)

1. Louis, D. N., H. Ohgaki, O. D. Wiestler, and W. K. Cavenee. 2007. WHO Classification of Tumours of the Central Nervous System, 4th ed. International Agency for Research on Cancer, Lyon.
2. Ohgaki, H., and P. Kleihues. 2013. The definition of primary and secondary glioblastoma. Clin. Cancer Res. 19:764–772.
3. Armengol, G., F. Rojo, J. Castellví, et al. 2007. 4E-binding protein 1: a key molecular “funnel factor” in human cancer with clinical implications. Cancer Res. 67:7551–7555.
4. Ramon, Y., S. Cajal, L. De Mattos-Arruda, N. Sonenberg, J. Cortes, and V. Peg. 2014. The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets. Clin. Transl. Oncol. 16:937–941.
5. Castellvi, J., A. Garcia, C. Ruiz-Marcellan, et al. 2009. Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis. Hum. Pathol. 40:1418–1426.
6. Pons, B., V. Peg, M. A. Vázquez-Sánchez, et al. 2011. The effect of p-4E-BP1 and p-eIF4E on cell proliferation in a breast cancer model. Int. J. Oncol. 39:1337–1345.
7. Castellvi, J., A. Garcia, F. Rojo, et al. 2006. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 107:1801–1811.
8. Benavente, S., R. Vergés, E. Hermosilla, et al. 2009. Overexpression of phosphorylated 4E-BP1 predicts for tumor recurrence and reduced survival in cervical carcinoma treated with postoperative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 75:1316–1322.
9. Cedrés, S., M. A. Montero, P. Martinez, et al. 2012. Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer 77:192–198.
10. Rojo, F., L. Najera, J. Lirola, et al. 2007. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin. Cancer Res. 13:81–89.
11. Horbinski, C., J. Kofler, L. M. Kelly, G. H. Murdoch, and M. N. Nikiforova. 2009. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J. Neuropathol. Exp. Neurol. 68:1319–1325.
12. Ferrandiz-Pulido, C., E. Masferrer, A. Toll, et al. 2013. mTOR signaling pathway in penile squamous cell carcinoma: pmTOR and peIF4E over expression correlate with aggressive tumor behavior. J. Urol. 190:2288–2295.
13. Roh, M. S., J. H. Lee, K. W. Kang, et al. 2015. Phosphorylated 4E-binding protein 1 expression is associated with poor prognosis in small-cell lung cancer. Virchows Arch. 467:667–673.
14. Yoshizawa, A., J. Fukuoka, S. Shimizu, et al. 2010. Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin. Cancer Res. 16:240–248.
15. Korkolopoulou, P., G. Levidou, E. A. El-Habr, et al. 2012. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas. Histopathology 61:293–305.
16. Ermoian, R. P., T. Kaprealian, K. R. Lamborn, et al. 2009. Signal transduction molecules in gliomas of all grades. J. Neurooncol. 91(1):19–26.
17. Riemenschneider, M. J., R. A. Betensky, S. M. Pasedag, and D. N. Louis. 2006. AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res. 66:5618–5623.
18. Greenberg, V. L., and S. G. Zimmer. 2005. Paclitaxel induces the phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1 through a Cdk1-dependent mechanism. Oncogene 24:4851–4860.
19. Carroll, M., and K. L. Borden. 2013. The oncogene eIF4E: using biochemical insights to target cancer. J. Interferon Cytokine Res. 33:227–238.
20. De Benedetti, A., and J. R. Graff. 2004. eIF-4E expression and its role in malignancies and metastases. Oncogene 23:3189–3199.
21. Pettersson, F., S. V. Del Rincon, and W. H. Miller. 2014. Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond. Expert Opin. Ther. Targets 18:1035–1048.
22. Crew, J. P., S. Fuggle, R. Bicknell, D. W. Cranston, A. de Benedetti, and A. L. Harris. 2000. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br. J. Cancer 82:161–166.
23. Graff, J. R., B. W. Konicek, R. L. Lynch, et al. 2009. eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res. 69:3866–3873.
24. Furic, L., L. Rong, O. Larsson, et al. 2010. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc. Natl Acad. Sci. USA 107:14134–14139.
25. Matthews-Greer, J., A. DeBenedetti, A. Tucker, S. Dempsey, D. Black, E. Turbat-Herrera. 2002. A model for angiogenesis in HPV-mediated cervical cancer. J. Appl. Res. 2:63–73.
26. Rosenwald, I. B., J. J. Chen, S. Wang, L. Savas, I. M. London, and J. Pullman. 1999. Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 18:2507–2517.
27. Seki, N., T. Takasu, K. Mandai, et al. 2002. Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. Clin. Cancer Res. 8:3046–3053.
28. Gu, X., L. Jones, M. Lowery-Norberg, and M. Fowler. 2005. Expression of eukaryotic initiation factor 4E in astrocytic tumors. Appl. Immunohistochem. Mol. Morphol. 13:178–183.
29. Haydon, M. S., J. D. Googe, D. S. Sorrells, G. E. Ghali, and B. D. Li. 2000. Progression of eIF4e gene amplification and overexpression in benign and malignant tumors of the head and neck. Cancer 88:2803–2810.
30. Hou, J., F. Lam, C. Proud, and S. Wang. 2012. Targeting Mnks for cancer therapy. Oncotarget 3:118–131.
31. Martínez, A., M. Sesé, J. H. Losa, et al. 2015. Phosphorylation of eIF4E Confers Resistance to Cellular Stress and DNA-Damaging Agents through an Interaction with 4E-T: A Rationale for Novel Therapeutic Approaches. PLoS ONE 10:e0123352.
32. Bhat, M., N. Robichaud, L. Hulea, N. Sonenberg, J. Pelletier, and I. Topisirovic. 2015. Targeting the translation machinery in cancer. Nat. Rev. Drug Discov. 14:261–278.
33. Fan, S., S. S. Ramalingam, J. Kauh, Z. Xu, F. R. Khuri, and S. Y. Sun. 2009. Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol. Ther. 8:1463–1469.
34. Robichaud, N., S. V. del Rincon, B. Huor, et al. 2015. Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3. Oncogene 34:2032–2042.
35. Assouline, S., B. Culjkovic, E. Cocolakis, et al. 2009. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 114:257–260.
36. Grzmil, M., R. M. Huber, D. Hess, et al. 2014. MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas. J. Clin. Invest. 124:742–754.
37. Pettersson, F., S. V. Del Rincon, A. Emond, et al. 2015. Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis. Cancer Res. 75:1102–1112.